審議結果報告書 平成 28 - pmda.go.jp
審議結果報告書 平成28年 11月 16日 医薬・生活衛生局医薬品審査管理課 [販売名] ベムリディ錠25 mg [一般名] テノホビル アラフェナミドフマル酸塩
Download 審議結果報告書 平成 28 - pmda.go.jp
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Advertisement
Documents from same domain
339 - pmda.go.jp
www.pmda.go.jp医薬品・医療機器等安全性情報 No.339 −3− 2016年12月 1 ミルナシプラン塩酸塩,デュロキセチン塩酸塩 及びベンラファキシン塩酸塩製剤の自動車運転等
Report on the Deliberation Results - pmda.go.jp
www.pmda.go.jpReport on the Deliberation Results . December 3, 2014 . Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau . Ministry of Health, Labour and Welfare
Report, Results, Report on the deliberation results, Deliberation
Filgrastim, Lenograstim, Nartograstim, Pegfilgrastim
www.pmda.go.jpPharmaceuticals and Medical Devices Agency This English version is intended to be a reference material for the convenience of users. In the event of
Pharmaceuticals and Medical Devices Safety …
www.pmda.go.jpPharmaceuticals and Medical Devices Safety Information No. 347 - 3 - October 2017 Abbreviations ADR Adverse drug reaction Alb Albumin ALP Alkaline phosphatase
Information, Devices, Pharmaceutical, Medical, Safety, Pharmaceuticals and medical devices safety, Pharmaceuticals and medical devices safety information
The Ministry of Health, Labour and Welfare …
www.pmda.go.jpThe Ministry of Health, Labour and Welfare Ministerial Notification No. 519 Pursuant to Paragraph 1, Article 41 of the Pharmaceutical AŠairs Law (Law No.
Labour, Welfare, Notification, Ministerial, Labour and welfare ministerial notification no
2018.3 No. 267 - pmda.go.jp
www.pmda.go.jp1 2018. 3. dsu no. 267 重 要 生薬 510 サンシシ 2 漢方製剤 520 茵蔯蒿湯 3 温清飲 4 黄連解毒湯 3 加味帰脾湯 4
PMDAからの医薬品適正使用のお願い - pmda.go.jp
www.pmda.go.jp医薬品医療機器総合機構PMDA. からの医薬品適正使用のお願い http://www.pmda.go.jp/safety/info-services/drugs/0001.html
IMPURITIES GUIDELINE FOR RESIDUAL S Q3C(R5)
www.pmda.go.jpinternational conference on harmonisation of technical requirements for registration of pharmaceuticals for human use ich harmonised tripartite guideline impurities: guideline for …
Guidelines, Impurities, Guideline for, Guideline impurities, Impurities guideline for
2.7.2 summary of clinical pharmacology Studies
www.pmda.go.jpCONFIDENTIAL RM2003/00379/00 2.7.2 Summary of Clinical Pharmacology 4 ABBREVIATIONS 3TC lamivudine (EPIVIRƒ) ABC abacavir (ZIAGENƒ)AE Adverse Event AUC0-t,ss Area under the drug concentration-time curve from 0 to time t at steady state AUC∞ Area under the plasma concentration versus time curve from time 0 and …
Clinical, Summary, Pharmacology, 2 summary of clinical pharmacology, 2 summary of clinical pharmacology 4
Related documents
Introductory Guide for MedDRA - WHO
www.who.intThis Introductory Guide is written in English and is intended only for use with the English version of MedDRA. Additional Introductory Guides have been developed to
MedDRAについて - dsrujp.org
www.dsrujp.orgMedDRA: Medical Dictionary for Regulatory Activities Terminology •MedDRAは、医薬品に関連 する国際間の情報交換を迅 速かつ的確に行うため、国
의약품 부작용에 관한 국제 분류체계인 WHO-ART와 …
kccp.or.kr한국임상약학회지 제17권 제1호 Kor. J. Clin. Pharm., Vol. 17, No. 1. 2007 46 의약품 부작용에 관한 국제 분류체계인 WHO-ART와 MedDRA의 비교분석
平成 28 30 - pmda.go.jp
www.pmda.go.jp審査報告書 平成29 年1 月18 日 独立行政法人医薬品医療機器総合機構 承認申請のあった下記の医薬品にかかる医薬品医療機器総合機構での審査結果は、以下のとおりであ
01 OS MedDRAとは201103(final).ppt [互換モード]
www.pmrj.jp2 MedDRAの開発とリリース 1990~英国内のデータベース用の用語集⇒欧州内での検討 ICHで取り上げられる前に用語集作成の取組みを開始